Drug Profile
Ivabradine - Servier
Alternative Names: AMG-998; Coralan; Coraxan; Corlanor; Corlentor; Ivabradine hydrochloride; LANCORA; ONO-1162; Procoralan; S-16257; S-16257-2; S-57Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Servier
- Developer Amgen; Ono Pharmaceutical; Servier; University of California, San Diego
- Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Hyperpolarisation activated cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Angina pectoris; Chronic heart failure
- Phase III Coronary artery disease; Tachycardia
- Phase II Low cardiac output
Most Recent Events
- 08 Aug 2022 Ono Pharmaceutical completed a phase-III clinical trial in Chronic heart failure in Japan (PO) (JapicCTI-153007)
- 29 Jun 2021 Dana-Farber Cancer Institute and Amgen terminates a phase II trial in Chronic heart failure in USA (PO) as funding terminated (NCT03137537)
- 06 Apr 2021 Dana-Farber Cancer Institute and Amgen suspends a phase II trial in Chronic heart failure in USA (PO) as funding terminated (NCT03137537)